Da	te:2021/9/4				
Υo	ur Name:_Mei Zhao				
Ma	nuscript Title: Huma	n menstrual blood-derive	ed mesenchymal stem cells regulation of the EGF/Ras p21		
pa	thway as a potential therap	eutic target for thin endo	metrium		
Ma	Nanuscript number (if known):				
In <sup>1</sup>	the interest of transparency	, we ask you to disclose a	ıll relationships/activities/interests listed below that are		
rel	ated to the content of your	manuscript. "Related" me	eans any relation with for-profit or not-for-profit third		
pa	rties whose interests may be	e affected by the content	of the manuscript. Disclosure represents a commitment		
	<u> </u>	=	s. If you are in doubt about whether to list a		
rel	ationship/activity/interest,	it is preferable that you d	lo so.		
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>		
to	• •	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.		
	·		·		
	tem #1 below, report all su time frame for disclosure i	•	ed in this manuscript without time limit. For all other items		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as	· ·		
		needed)			
		Time frame: Since the initi	al planning of the work		
	All support for the present	None			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: pas	st 36 months		
	Grants or contracts from	None			
	any entity (if not indicated				
	in item #1 above).				
	Royalties or licenses	None			

Consulting fees

None

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2021/9/4		
Yo	ur Name:_ Fengli Chi		
Ma	nuscript Title: Huma	an menstrual blood-derive	ed mesenchymal stem cells regulation of the EGF/Ras p21
pat	hway as a potential therap	eutic target for thin endo	metrium
Ma	nuscript number (if known)	):	
related to the mean related to the mean related to the mean related to the mean related to the r	ated to the content of your ties whose interests may be transparency and does not ationship/activity/interest, ationship questions apply nuscript only.  The author's relationships/act the epidemiology of hypertidication, even if that medication.	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be ension, you should declar cation is not mentioned in	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all su time frame for disclosure i	· ·	ed in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

Consulting fees

\_None

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2021/9/4			
	ur Name:_ Tingyu Zhang			
Ma	anuscript Title: Huma	an menstrual blood-derive	ed mesenchymal stem cells regulation of the EGF/Ras p2	1
pa	thway as a potential therap	eutic target for thin endo	metrium	
Ma	anuscript number (if known)	:		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a	
iei	ationsinp/activity/interest,	it is preferable that you u	0.50.	
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertaine all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other ite	ms,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initi	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials,	None		
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	st 36 months	
2	Grants or contracts from	None		
	any entity (if not indicated in item #1 above).			
2	Royalties or licenses	None		
,	Moyalties of licelises	None		

Consulting fees

\_None

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2021/9/4			
Ma	anuscript Title: Huma	an menstrual blood-derive	ed mesenchymal stem cells regulation of the EGF/Ras p21	
pa	thway as a potential therap	eutic target for thin endo	metrium	
Ma	anuscript number (if known)	):		
rel pa	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment	
	Nature:			
	= -	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to	the epidemiology of hypert	ension, you should declar	e all relationships with manufacturers of antihypertensive	
	· -	• •	ed in this manuscript without time limit. For all other items	5,
		Name all entities with	Specifications/Comments	
		_		
		none (add rows as		
		Time frame: Since the initi	al planning of the work	
L		None		
	•			
	No time limit for this item.			
		<b>—</b>		
)	Crants or contracts from		st 56 months	
-		None		
	, , ,			
<b>\</b>	·	None		
,	Noyalties of ficelises	IVOITE		

Consulting fees

None

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:2021/9/4		
	r Name:_ Kunming Li		
Ma	nuscript Title: Huma	an menstrual blood-derive	ed mesenchymal stem cells regulation of the EGF/Ras p21
pat	hway as a potential therap	eutic target for thin endo	metrium
Ma	nuscript number (if known	):	
rela par to t	ted to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	following questions apply nuscript only.	to the author's relationsh	hips/activities/interests as they relate to the <u>current</u>
to t		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	em #1 below, report all su time frame for disclosure i		ed in this manuscript without time limit. For all other items
		Name all autition with	Supplifications / Summants
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution,
		needed)	
		Time frame: Since the initi	al planning of the work
	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	Consulta an acoustica et a fina con	Time frame: pas	st 36 months
	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
	Royalties or licenses	None	
	noyalties of licelises	NOTIC	

Consulting fees

\_None

			_ <del>_</del>
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	•		
7	Support for attending	None	
	meetings and/or travel		
	g .		
8	Patents planned, issued or	None	
0	pending	None	
	perialing		
9	Participation on a Data	None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement: